Cargando…

Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysis

BACKGROUND: Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia mediated by IgM autoantibodies that trigger hemolysis via classical complement pathway. Increased incidence of thrombotic events (TEs) has been reported in patients with other forms of hemolysis. The incidence of TEs in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broome, Catherine M., Cunningham, Julia M., Mullins, Megan, Jiang, Xiaohui, Bylsma, Lauren C., Fryzek, Jon P., Rosenthal, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Article: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292660/ https://www.ncbi.nlm.nih.gov/pubmed/32548562 http://dx.doi.org/10.1002/rth2.12333

Ejemplares similares

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States
por: Broome, Catherine M., et al.
Publicado: (2022)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Post‐thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study
por: de Kleijn, Robert J. C. M. F., et al.
Publicado: (2022)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Thrombotic risk determined by rare and common SERPINA1 variants in a population‐based cohort study
por: Manderstedt, Eric, et al.
Publicado: (2022)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Thrombotic Events in COVID-19 Patients Undergoing Convalescent Plasma Therapy: A Systematic Review
por: Yu, Philip, et al.
Publicado: (2021)

The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
por: Bissola, Anna-Lise, et al.
Publicado: (2022)

Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura
por: Borogovac, Azra, et al.
Publicado: (2022)

P1539: SEASONALITY OF HEALTHCARE RESOURCE UTILIZATION AMONG COLD AGGLUTININ DISEASE AMONG PATIENTS IN DENMARK: A RETROSPECTIVE ANALYSIS
por: Fryzek, J., et al.
Publicado: (2022)

Vaccine-Induced Thrombotic Thrombocytopenia: Novelty Testing in the Diagnostic Work-up?
por: Cacciola, Rossella Rosari, et al.
Publicado: (2021)

A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia
por: Lee, Christine S.M., et al.
Publicado: (2022)

The Impact of Degree of Anticoagulation on Thrombotic and Other Complications in Hospitalized COVID-19 Patients
por: Zheng, Rena, et al.
Publicado: (2021)

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
por: Schönborn, Linda, et al.
Publicado: (2022)

Comparison of Thrombotic Complications in Critically Ill Patients between COVID-19 and Mers-COV
por: Al Raizah, Abdulrahman, et al.
Publicado: (2021)

Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura
por: Shin, Jin-Sup, et al.
Publicado: (2022)

Thrombotic Events in COVID-19 Patients and Its Comparison with Other Non-Sars-Cov-2 Respiratory Viruses
por: Tan, Jing Yuan, et al.
Publicado: (2020)

A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
por: Falter, Tanja, et al.
Publicado: (2023)

A Rare Case of Mild COVID-19 Disease Associated with Type 1 Cryoglobulinemia and Thrombotic Thrombocytopenic Purpura
por: Naqvi, Syed Mujtaba, et al.
Publicado: (2021)

Cold Agglutinin Disease
por: Gabbard, Amy P., et al.
Publicado: (2020)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

COVID-19 Diagnosis and Its Impact on Thrombotic Risk in a Cohort of Patients Simultaneously Hospitalized Due to Acute Respiratory Distress Syndrome
por: Coy-Canguçu, Andréa, et al.
Publicado: (2021)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014)

Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients
por: Stals, Milou A. M., et al.
Publicado: (2021)

Characteristics of pain, other symptoms and function in pediatric post‐thrombotic syndrome
por: Avila, Maria L., et al.
Publicado: (2018)

Assessing the clinical probability of pulmonary embolism during pregnancy: The Pregnancy‐Adapted Geneva (PAG) score
por: Robert‐Ebadi, Helia, et al.
Publicado: (2021)

Citrullinated fibrinogen forms densely packed clots with decreased permeability
por: Varjú, Imre, et al.
Publicado: (2022)

Risk of neonatal hypothyroidism in newborns from mothers exposed to CTPA during pregnancy: Ancillary data from a prospective outcome study
por: Righini, Marc, et al.
Publicado: (2022)

Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study
por: Nakano, Yoshihisa, et al.
Publicado: (2022)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry
por: Kruijt, Mirjam, et al.
Publicado: (2021)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation
por: Li, Yanni, et al.
Publicado: (2020)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8n7ua8r6p6eb6rslmnpbp9fr7p